Abiopharma

🔍 Prasad Raju (Executive)

Company: CRISPR Therapeutics AG (CRSP)

Report Date: 2026-03-20

Detailed Transactions and Holdings:

• Acquired 6,250 shares of Common Shares (Direct)
  Date: 2026-03-20 | Code: M | equity_swap_involved: false | shares_owned_after: 19,273.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 3,708 shares of Common Shares at $46.78 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: false | shares_owned_after: 15,565.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 38,499 shares of Stock Option (Right to Buy) at $46.24 per share (Derivative)
  Date: 2026-03-20 | Code: A | Expires: 2036-03-20 | equity_swap_involved: false | shares_owned_after: 38,499.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Acquired 27,500 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-20 | Code: A | equity_swap_involved: false | shares_owned_after: 27,500.00 | transaction_form_type: 4 | Footnotes: F2, F1, F5, F5
• Sold 6,250 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-20 | Code: M | equity_swap_involved: false | shares_owned_after: 12,500.00 | transaction_form_type: 4 | Footnotes: F2, F1, F2, F6, F6

Footnotes:

• F1: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
• F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
• F3: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
• F4: This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.
• F5: This restricted stock unit award was granted on March 20, 2026 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.
• F6: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.